Drug Trial Radar · NCT06693765
A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of AZD4144 in Participants With Severe Renal Impairment, End-stage Kidney Disease, and in Healthy Participants
Last checked: Nov 19, 2026Latest source record: Apr 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
41
Actual
Start
Nov 18, 2024
Primary completion
Apr 23, 2025
Study completion Apr 23, 2025
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- Collaborators
- Parexel
- First posted
- Nov 18, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A study to investigate the pharmacokinetics, safety, and tolerability of AZD4144 in participants with severe renal impairment, end-stage kidney disease, and in healthy participants.
Conditions
- Renal Impairment
- End-stage Kidney Disease
- Healthy Participants
Interventions
AZD4144Drug
AZD4144 will be administered orally.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Observed maximum plasma concentration (Cmax)Time frame: From Day 1 to Day 14
- Area under the plasma concentration-time curve from time zero extrapolated to infinity (AUCinf)Time frame: From Day 1 to Day 14
- Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration (AUClast)Time frame: From Day 1 to Day 14
- Apparent total body clearance (CL/F)Time frame: From Day 1 to Day 14
- Non-renal clearance of drug from plasma (CLNR/F)Time frame: From Day 1 to Day 14
- Apparent volume of distribution based on the terminal phase (Vz/F)Time frame: From Day 1 to Day 14
- Terminal elimination half-life (t½λz)Time frame: From Day 1 to Day 14
- Renal clearance of drug from plasma (CLR)Time frame: From Day 1 to Day 4
- Amount excreted (Ae)Time frame: From Day 1 to Day 4
- Percentage of dose excreted unchanged in urine (fe)Time frame: From Day 1 to Day 4
- Number of Treatment Emergent Adverse Events (TEAEs)Time frame: From Day 1 to Follow-up (Day 14/28)
Locations
2 sites in 2 countries. Site status is shown where the registry gives one.
Research Site
Sofia, Bulgaria
Research Site
Bucharest, Romania
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.